Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390076 | 0.77 | MAPT (0.67) | ALDH1A1GAAMAPTKDM4ETP53 | |
| SCHEMBL4390080 | 0.77 | MAPT (0.67) | ALDH1A1GAAMAPTKDM4ETP53 | |
| SCHEMBL14055607 | 0.73 | POLB (0.43) | ALDH1A1GAAKDM4E | |
| SCHEMBL15882624 | 0.73 | MAPT (0.41) | MAPTTP53 | |
| SCHEMBL10154049 | 0.70 | MAPT (0.44) | MAPTTP53 | |
| SCHEMBL2634053 | 0.69 | CA1 (0.37) | MAPTTP53 | |
| SCHEMBL14822900 | 0.68 | HPGD (0.39) | MAPTTP53 | |
| SCHEMBL13590689 | 0.66 | KDM4E (0.75) | ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL13409940 | 0.66 | HPGD (0.35) | MAPTTP53 | |
| SCHEMBL14075554 | 0.66 | CA1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | ALDH1A1 169/4885GAA 288/4885MAPT 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.